“This article illuminates the biology behind EDG-5506, demonstrating that modulation of fast skeletal muscle contraction protects against muscle injury, degeneration and fibrosis in models of DMD,” ...
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the ...
- All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101 Q4W Demonstrated Consistent Splicing Correction with a 19% Mean Improvement Across 22-Gene Panel at 3 Months - - Improvement in ...
Inmune Bio Inc., together with a collaborator at University of California, Irvine School of Medicine, has shown targeting soluble TNF (sTNF) using a dominant-negative TNF (DN-TNF) biologic ...
Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...
- Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration - Phase 1a data shows favorable pharmacokinetic (PK) profile of ...
Satellos Bioscience (MSCLF) announced new data further demonstrating tolerability and initial efficacy of SAT-3247 in adults with Duchenne muscular dystrophy at the 30th Annual Congress of the World ...
A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help control chronic muscle inflammation in Duchenne muscular dystrophy (DMD), a ...
WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback